This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): doxercalciferol
Description: Doxercalciferol, the active ingredient in Hectorol, is a synthetic vitamin D analog that undergoes metabolic activation in vivo to form the biologically active form of vitamin D2. Vitamin D regulates calcium and phosphorus homeostasis and bone mineralization.
Deal Structure: Genzyme acquired Bone Care International on July 1, 2005, which included the acquisition of Hectorol.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Pink Sheet Hectorol I.V. Clinical Protocols
Pink Sheet Hectorol I.V. FDA Reviewers
Pink Sheet Hectorol I.V. Clinical Development
Pink Sheet Bone Care Hectorol sNDA "approvable"
Additional information available to subscribers only: